2.10
0.12 (6.06%)
| Penutupan Terdahulu | 1.98 |
| Buka | 1.98 |
| Jumlah Dagangan | 50,829 |
| Purata Dagangan (3B) | 402,927 |
| Modal Pasaran | 97,206,056 |
| Harga / Jualan (P/S) | 2.13 |
| Harga / Buku (P/B) | 1.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Mar 2025 |
| Margin Keuntungan | -246.06% |
| Margin Operasi (TTM) | -149.40% |
| EPS Cair (TTM) | -2.28 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 21.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.37% |
| Nisbah Semasa (MRQ) | 4.89 |
| Aliran Tunai Operasi (OCF TTM) | -54.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.62 M |
| Pulangan Atas Aset (ROA TTM) | -35.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Aadi Bioscience, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Purata | -0.38 |
|
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.10% |
| % Dimiliki oleh Institusi | 50.02% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |